Brief: Therapeutic Solutions International Prepares To Apply For EUA For Its FDA Phase Iii Covid-19 Stem Cell Therapy Jadicell™
16/08/2021 14:16
Aug 16 (Reuters) - Therapeutic Solutions International Inc
TSOI.PK :
* THERAPEUTIC SOLUTIONS INTERNATIONAL PREPARES TO APPLY FOR
EMERGENCY USE AUTHORIZATION (EUA) FOR ITS FDA PHASE III COVID-19
STEM CELL THERAPY JADICELL™
Source text for Eikon: ID:nPn6CjXgFa
Further company coverage: TSOI.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Therapeutic Solutions International
See all newsBrief: Therapeutic Solutions International Files For Orphan Drug Designation Use Of Jadicell Adult Stem Cells
Brief: Therapeutic Solutions International Files To Initiate Phase Iii Clinical Trial For Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive Covid-19 Data With Jadicell Stem Cell Therapy
Brief: Therapeutic Solutions International Files With FDA To Expand Ongoing Phase III Clinical Trial To Include All Causes Of Acute Respiratory Distress Syndrome
Brief: Therapeutic Solutions Granted Emergency IND By FDA For Stem Cell Therapy
Brief: Therapeutic Solutions International Completes Purchase Of FDA Phase Iii Jadicell Stem Cell Investigational New Drug Application From University Of Miami